{"id":"sector-healthcare","category":"sector","title":"Healthcare Sector Context","summary":"Biosimilar wave, drug pricing regulation, managed care dynamics, biotech pipeline.","trigger":{"always":false,"sectors":["Health Care","Healthcare"],"tickers":["UNH","CVS","ABT","JNJ","PFE","MRNA","ABBV","LLY","BMY","ISRG"],"regimes":[]},"ttl_hours":168,"content":{"sector_outlook":"mixed","verdict":"Large-cap managed care (UNH, ELV) remains defensive. Drug pricing headwinds from IRA negotiations hitting specialty pharma. Biotech pipeline catalysts high-risk/high-reward.","key_drivers":["GLP-1 obesity drug demand — LLY and NVO capturing massive TAM","IRA drug price negotiation list expanding (10 → 20+ drugs)","Biosimilar adoption pressure on originators in Q3/Q4 2026"],"key_risks":["CMS audit scrutiny on Medicare Advantage plans — UNH, CVS MLR compression","FDA CMC holds slowing biosimilar approvals (short-term relief for originators)","Pipeline failures — binary risk for any single-asset biotechs"],"favored_tickers":["UNH","LLY","ISRG"],"cautious_tickers":["CVS","PFE"],"downstream_impacts":{"FOMC_hike":"Mildly positive — healthcare is defensive, but biotech hurt by rate rises","weak_economy":"Outperforms — non-cyclical demand for healthcare services","vix_spike":"Defensive rotation into managed care ETFs (XLV)"}}}